In the Margins
Valeant Pharmaceuticals has named Mason Morfit, a partner at activist hedge fund ValueAct Capital, to its board of directors. Morfit previously served on the embattled specialty drugmaker's board from 2007 to 2014; ValueAct is one of Valeant's largest shareholders. Read the original story from Forbes.
Most Read
Total compensation paid to independent mutual fund directors in 2023 increased, though the difference was smaller than in the year prior, according to industry data obtained ...
The Putnam Funds board has new leadership and a new independent member following the retirement of Kenneth Leibler, who chaired the board for six years and ...
Independent Chairman Hassell McClellan and the John Hancock Funds board made progress this summer on a years-long board refreshment effort, but they're not done yet. McClellan ...
The Securities and Exchange Commission has been accused of "over-regulation" in recent years as it has proposed and finalized dozens of rules in a relatively short ...